Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS

Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS

Experimental: Efgartigimod
Receive efgartigimod IV 10mg/kg during weekly infusions during a treatment period of 24 weeks
Drug: Efgartigimod
Efgartigimod IV 10 mg/kg infusion qw for 24 weeks. Participants will be randomized to receive efgartigimod IV 10 mg/kg or matching placebo in a 2:1 ratio, respectively

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 2, 2022Comments OffCardiology | Cardiology Clinical Trials | Cardiology Studies | ClinicalTrials.gov | Drug Trials Near Me | US National Library of Medicine
Comments